seloken stungulyf, lausn 1 mg/ml
recordati ireland limited* - metoprololum tartrat - stungulyf, lausn - 1 mg/ml
bloxazoc forðatafla 25 mg
krka d.d. novo mesto - metoprololum súkkínat - forðatafla - 25 mg
bloxazoc forðatafla 200 mg
krka d.d. novo mesto - metoprololum súkkínat - forðatafla - 200 mg
bloxazoc forðatafla 50 mg
krka d.d. novo mesto - metoprololum súkkínat - forðatafla - 50 mg
metoprolol alvogen (metoprolol ratiopharm) forðatafla 23,75 mg
alvogen ehf. - metoprololum súkkínat - forðatafla - 23,75 mg
metoprolol alvogen (metoprolol ratiopharm) forðatafla 47,5 mg
alvogen ehf. - metoprololum súkkínat - forðatafla - 47,5 mg
yesafili
viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - augnlækningar - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.
venlafaxine alvogen (venlafaxine portfarma) hart forðahylki 150 mg
alvogen ehf. - venlafaxinum hýdróklóríð - hart forðahylki - 150 mg
venlafaxine alvogen (venlafaxine portfarma) hart forðahylki 75 mg
alvogen ehf. - venlafaxinum hýdróklóríð - hart forðahylki - 75 mg
lucentis
novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - augnlækningar - lucentis er fram í fyrir fullorðna:meðferð neovascular (blautur) aldri-tengjast ský á auga (rÍsa)meðferð sjón skert vegna æðu neovascularisation (cnv)meðferð sjón skert vegna sykursýki ský bjúg (dme)meðferð sjón skert vegna ský bjúg efri að sjónhimnu æð stíflu (útibú rvo eða central rvo).